In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $52.00. Sam Slutsky has given his Buy rating due to ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients presenting with ocular myasthenia gravis (MG).

- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December ...

Immunovant has advanced its mission to claim an unoccupied area of the competitive anti-FcRn space, reporting phase 2 data that support its attempt to be the first to market in Graves’ disease. The ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a price target of $48.00. Thomas Smith has given his Buy rating ...

- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - ...

Please provide your email address to receive an email when new articles are posted on . FcRn receptors have received FDA approvals in generalized myasthenia gravis. Studies of FcRn receptors in RA and ...

Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...

Dutch biotech Argenx is hoping to build a portfolio of autoimmune treatments around Vyvgart, which received FDA approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak ...

The Human FcRn Binding Kit (TR-FRET) uses a homogeneous (no-wash) competition TR-FRET technology, which stands for Time-Resolved Fluorescence Resonance Energy Transfer, to assess the interaction ...

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the ...